The Michael J. Fox Foundation - Therapeutics Pipeline Program | Research Funding
Event details
| Date | 27.07.2023 |
| Category | Call for proposal |
Aim: The Michael J. Fox Foundation (MJFF) funds research to better define, measure, and treat Parkinson’s disease as well as critical tools and other resources to advance that research. The Pre-clinical Therapeutics Pipeline Program seeks to accelerate the path of the therapeutic pipeline towards the clinic through the support of ambitious and scientifically robust pre-clinical studies aiming at developing and/or testing treatments and/or interventions that can address the unmet needs of people with PD. To meet this goal, we are currently only accepting applications from industry groups and academia-industry partnerships.
When considering applications submitted to this program, MJFF is interested in programs that aim to:
For this program, MJFF will not consider proposals focused on the following:
Duration: 24 months
Eligibility: Applications may be submitted by researchers or clinicians in:
How to Apply: The two-stage application process begins with an LOI, which can be submitted on a rolling basis on the MJFF Grant Portal. Instructions for submitting LOIs can be found here. Selected applicants will be notified within two weeks, and will be invited to submit a full proposal by one of the four deadlines (see below). Budgets should be formulated to include 15% OH.
Deadlines (full proposals): 12 January 2023
23 March 2023
25 May 2023
27 July 2023
Further information
When considering applications submitted to this program, MJFF is interested in programs that aim to:
- Identify, validate or develop novel pharmacological and non-pharmacological therapies through any of the pre-clinical stages of the therapeutics discovery and development process (from early screening campaigns to pre-clinical characterization nd testing). Therapies can address any PD motor or non-motor symptoms or could be aimed at preventing, stopping or delaying disease progression.
- Test repurposed/repositioned therapies hitting priority PD pathways/targets in pre- clinical PD models.
For this program, MJFF will not consider proposals focused on the following:
- Applications for target identification, proposing early discovery studies to identify new targets (e.g., large-scale screening or genomic/transcriptomic analyses).
- Applications proposing genetic model systems and/or genetic manipulation to validate biological targets, except if used as therapeutic approach(es).
- Clinical trials
Duration: 24 months
Eligibility: Applications may be submitted by researchers or clinicians in:
- U.S. and non-U.S. biotechnology/pharmaceutical/medical device companies, or other publicly or privately held for-profit entities; and
- U.S. and non-U.S. public and private non-profit entities, such as universities, colleges, hospitals, laboratories, units of state and local governments, and eligible agencies of the federal government in collaboration with biotechnology/pharmaceutical/medical device companies, or other publicly or privately held for-profit entities.
- Post-doctoral fellows are eligible to apply as co-investigators with the designation of an administrative primary investigator who directs the laboratory in which the fellow will conduct research.
How to Apply: The two-stage application process begins with an LOI, which can be submitted on a rolling basis on the MJFF Grant Portal. Instructions for submitting LOIs can be found here. Selected applicants will be notified within two weeks, and will be invited to submit a full proposal by one of the four deadlines (see below). Budgets should be formulated to include 15% OH.
Deadlines (full proposals): 12 January 2023
23 March 2023
25 May 2023
27 July 2023
Further information
- More information about the program is available here
- For any other questions, please contact the Research Office
Practical information
- General public
- Free